Adrenocortical carcinoma: experience in 45 patients

Area of Science:

• Endocrinology
• Oncology
• Cancer Research

Background:

• Adrenocortical carcinoma is a rare and aggressive malignancy.
• Current treatment outcomes for adrenocortical carcinoma remain unsatisfactory.
• Understanding prognostic factors and treatment efficacy is crucial.

Purpose of the Study:

• To retrospectively analyze survival rates in patients with adrenocortical carcinoma.
• To evaluate the efficacy of mitotane and chemotherapy, alone or in combination.
• To identify factors influencing disease-free interval and overall survival.

Main Methods:

• Retrospective study of 45 patients diagnosed with adrenocortical carcinoma.
• Analysis of patient data including tumor stage, treatment regimens (mitotane, chemotherapy, combination), and survival outcomes.
• Statistical comparison of survival rates across different treatment groups and disease stages.

Main Results:

• Overall 5-year survival rate was 29%, with significantly lower rates for advanced stages (Stage III-IV: 12%) compared to early stages (Stage I-II: 70%).
• Patients receiving mitotane plus chemotherapy showed similar survival to chemotherapy alone, but significantly longer survival than mitotane alone (p < 0.05).
• Adjuvant mitotane did not improve disease-free interval or survival compared to no adjuvant treatment.

Conclusions:

• Stage is a critical prognostic factor in adrenocortical carcinoma.
• Combination therapy involving mitotane and chemotherapy may offer survival advantages.
• Early detection and optimized therapeutic protocols are essential for improving patient outcomes in adrenocortical carcinoma.